0000000000587820

AUTHOR

Calvaruso

showing 4 related works from this author

Fibrosis staging in chronic hepatitis C: Analysis of discordance between transient elastography and liver biopsy

2009

Summary.  In chronic hepatitis C, transient elastography (TE) accurately identifies cirrhosis, but its ability to assess significant fibrosis (Metavir ≥ F2) is variable. Constitutional and liver disease-related factors may influence TE and here we examined the variables associated with differences. Three hundred consecutive hepatitis C virus (HCV)-RNA positive patients had biochemical tests, TE and a biopsy performed on the same day. The Dale model was used to identify the variables associated with discordance between biopsy and elastography results. In 97 patients (34.2%), TE and histological assessment were discordant. Seventy-six of 286 (26.6%) had stage ≥F2 and TE < 7.1 kPa (false negat…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisTransient elastographyHepatitis C virusBiopsyLiver fibrosismedicine.disease_causeGastroenterologySeverity of Illness IndexAminotranferases; Liver fibrosis; Transient elastography; Adult; Diagnostic Errors; Female; Hepatitis C Chronic; Histocytochemistry; Humans; Liver Cirrhosis; Male; Middle Aged; ROC Curve; Transaminases; Biopsy; Elasticity Imaging Techniques; Severity of Illness Index; Hepatology; Infectious Diseases; Virology; Medicine (all)Liver diseaseInternal medicineVirologyBiopsymedicineHumansDiagnostic ErrorsChronicAminotranferases liver fibrosis transient elastographyTransaminasesmedicine.diagnostic_testReceiver operating characteristicHepatologybusiness.industryHistocytochemistryMedicine (all)Hepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CInfectious DiseasesROC CurveLiver biopsyAminotranferasesElasticity Imaging TechniquesFemaleTransient elastographybusiness
researchProduct

Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects

2011

Introduction: The goal of antiviral therapy in patients with chronic hepatitis C is to slow or halt the progression of fibrosis and prevent the development of cirrhosis. Accordingly, antiviral treatment is proposed for a large population of patients with chronic hepatitis. Areas covered: The standard-of-care for chronic hepatitis C is the combination of pegylated IFN (PEG-IFN) and ribavirin. The use of these drugs has been correlated with a range of adverse effects, including influenza-like symptoms, hematological changes and neuropsychiatric disturbances. The effects of these adverse events associated with PEG-IFN therapy are manifold and are a major reason why patients decline or stop the…

medicine.medical_specialtyCirrhosisMedication Therapy ManagementPegylated interferon αInterferon alpha-2Antiviral AgentsPolyethylene Glycolschemistry.chemical_compoundFibrosisRibavirinmedicineHumansPharmacology (medical)In patientIntensive care medicineAdverse effectbusiness.industryRibavirinInterferon-alphaGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant ProteinsClinical PracticeTreatment OutcomechemistryPhysical therapyhepatitis Cbusiness
researchProduct

P496 Impact of ulcerative colitis on costs, work productivity and quality of life: a prospective study in a single referral centre

2019

medicine.medical_specialtyWork productivityQuality of life (healthcare)business.industryFamily medicineReferral centreGastroenterologymedicineGeneral Medicinemedicine.diseasebusinessProspective cohort studyUlcerative colitisJournal of Crohn's and Colitis
researchProduct

Models for non-alcoholic fatty liver disease: a link with vascular risk.

2008

Non alcoholic fatty liver disease (NAFLD) is often part of the metabolic syndrome which includes central obesity, dyslipidaemia, insulin resistance/type 2 diabetes mellitus and hypertension. In turn, NAFLD may be associated with an increased vascular risk. Several experimental models which express histological steatosis or steatohepatitis with fibrosis have been described. This review identifies those models of NAFLD with features of vascular risk.

medicine.medical_specialtyDiseasedigestive systemGastroenterologyInsulin resistanceNAFLD central obesity dyslipidaemia insulin resistance/type 2Risk FactorsInternal medicineDrug DiscoveryAnimalsHumansMedicineVascular DiseasesRisk factorPharmacologybusiness.industryFatty livernutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseasedigestive system diseasesFatty LiverDisease Models AnimalEndocrinologyInflammation MediatorsSteatosisMetabolic syndromeSteatohepatitisbusiness
researchProduct